Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Preexposure Prophylaxis for HIV - Where Do We Go from Here?
NEJM 367:459-461,462, Cohen, M.S. & Baden, L.R., 2012
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians
Stroke 39:227-230,7, Gattellari,M.,et al, 2008
Nonadherence to Antiepileptic Drugs and Increased Mortality: Findings from the RANsom Study
Neurol 71:1572-1578, Faught,E.,et al, 2008
Status Epilepticus at an Urban Public Hospital in the 1980s
Neurol 43:483-488, Lowenstein,D.H.&Alldredge,B.K., 1993
Comparison of Sprinkle Versus Syrup Formulations of Valproate for Bioavailability, Tolerance, and Preference
J Pediatr 120:634-638, Cloyd,J.C.,et al, 1992
Status Epilepticus
Am J Med 69:657-665, Aminoff,M.J.,et al, 1980